Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing “Psychedelics to Therapeutics”, is pleased
to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly-controlled subsidiary of Cybin, has achieved those milestones identified as Year 1 Q4 (ii), Year 2 Q1 (iv) and Year 2 Q1 (vii)
as contemplated by the terms of